NEW YORK (GenomeWeb News) – Compugen today reported that its third-quarter revenues declined to $6,000 from $90,000 year over year, as the firm plans to cut staff and reduce its expenses by 30 percent.
 
The Tel Aviv, Israel-based drug and biomarker discovery platform developer posted a net loss of $3.3 million, or $.12 per share, a 22 percent increase over a net loss of $2.7 million, or $.09 per share, for the third quarter of 2007.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.